These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24534762)

  • 1. Evaluation of polyglutamine repeats in autosomal dominant Parkinson's disease.
    Yamashita C; Tomiyama H; Funayama M; Inamizu S; Ando M; Li Y; Yoshino H; Araki T; Ichikawa T; Ehara Y; Ishikawa K; Mizusawa H; Hattori N
    Neurobiol Aging; 2014 Jul; 35(7):1779.e17-21. PubMed ID: 24534762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect.
    Gispert S; Kurz A; Waibel S; Bauer P; Liepelt I; Geisen C; Gitler AD; Becker T; Weber M; Berg D; Andersen PM; Krüger R; Riess O; Ludolph AC; Auburger G
    Neurobiol Dis; 2012 Jan; 45(1):356-61. PubMed ID: 21889984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats.
    Yu Z; Zhu Y; Chen-Plotkin AS; Clay-Falcone D; McCluskey L; Elman L; Kalb RG; Trojanowski JQ; Lee VM; Van Deerlin VM; Gitler AD; Bonini NM
    PLoS One; 2011 Mar; 6(3):e17951. PubMed ID: 21479228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.
    Elden AC; Kim HJ; Hart MP; Chen-Plotkin AS; Johnson BS; Fang X; Armakola M; Geser F; Greene R; Lu MM; Padmanabhan A; Clay-Falcone D; McCluskey L; Elman L; Juhr D; Gruber PJ; Rüb U; Auburger G; Trojanowski JQ; Lee VM; Van Deerlin VM; Bonini NM; Gitler AD
    Nature; 2010 Aug; 466(7310):1069-75. PubMed ID: 20740007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis.
    Conforti FL; Spataro R; Sproviero W; Mazzei R; Cavalcanti F; Condino F; Simone IL; Logroscino G; Patitucci A; Magariello A; Muglia M; Rodolico C; Valentino P; Bono F; Colletti T; Monsurrò MR; Gambardella A; La Bella V
    Neurology; 2012 Dec; 79(24):2315-20. PubMed ID: 23197749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spinocerebellar ataxia type 2: polyQ repeat variation in the CACNA1A calcium channel modifies age of onset.
    Pulst SM; Santos N; Wang D; Yang H; Huynh D; Velazquez L; Figueroa KP
    Brain; 2005 Oct; 128(Pt 10):2297-303. PubMed ID: 16000334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-expression Patterns between
    Keo A; Aziz NA; Dzyubachyk O; van der Grond J; van Roon-Mom WMC; Lelieveldt BPF; Reinders MJT; Mahfouz A
    Front Mol Neurosci; 2017; 10():399. PubMed ID: 29249939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large normal-range TBP and ATXN7 CAG repeat lengths are associated with increased lifetime risk of depression.
    Gardiner SL; van Belzen MJ; Boogaard MW; van Roon-Mom WMC; Rozing MP; van Hemert AM; Smit JH; Beekman ATF; van Grootheest G; Schoevers RA; Oude Voshaar RC; Comijs HC; Penninx BWJH; van der Mast RC; Roos RAC; Aziz NA
    Transl Psychiatry; 2017 Jun; 7(6):e1143. PubMed ID: 28585930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of SCA-2 and SCA-3 repeats in Parkinsonism: evidence of SCA-2 expansion in a family with autosomal dominant Parkinson's disease.
    Simon-Sanchez J; Hanson M; Singleton A; Hernandez D; McInerney A; Nussbaum R; Werner J; Gallardo M; Weiser R; Gwinn-Hardy K; Singleton AB; Clarimon J
    Neurosci Lett; 2005 Jul 1-8; 382(1-2):191-4. PubMed ID: 15911147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CAG repeats on the age at onset of patients with spinocerebellar ataxia type 2 in China.
    Li Y; Liu Z; Hou X; Chen Z; Shen L; Xia K; Tang B; Jiang H; Wang J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):793-799. PubMed ID: 34565721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts.
    Van Langenhove T; van der Zee J; Engelborghs S; Vandenberghe R; Santens P; Van den Broeck M; Mattheijssens M; Peeters K; Nuytten D; Cras P; De Deyn PP; De Jonghe P; Cruts M; Van Broeckhoven C
    Neurobiol Aging; 2012 May; 33(5):1004.e17-20. PubMed ID: 22035589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and distribution of polyQ disease intermediate-length repeat alleles in healthy Italian population.
    Mongelli A; Magri S; Salvatore E; Rizzo E; De Rosa A; Fico T; Gatti M; Gellera C; Taroni F; Mariotti C; Nanetti L
    Neurol Sci; 2020 Jun; 41(6):1475-1482. PubMed ID: 31940111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational prediction of the polyQ and CAG repeat spinocerebellar ataxia network based on sequence identity to untranslated regions.
    Spence JL; Wallihan S
    Gene; 2012 Nov; 509(2):273-81. PubMed ID: 22967711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATXN2 polyQ intermediate repeats are a modifier of ALS survival.
    Chiò A; Calvo A; Moglia C; Canosa A; Brunetti M; Barberis M; Restagno G; Conte A; Bisogni G; Marangi G; Moncada A; Lattante S; Zollino M; Sabatelli M; Bagarotti A; Corrado L; Mora G; Bersano E; Mazzini L; D'Alfonso S;
    Neurology; 2015 Jan; 84(3):251-8. PubMed ID: 25527265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating noncoding nucleotide repeat expansions in amyotrophic lateral sclerosis.
    Figley MD; Thomas A; Gitler AD
    Neurobiol Aging; 2014 Apr; 35(4):936.e1-4. PubMed ID: 24269018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease.
    Rosas I; Martínez C; Clarimón J; Lleó A; Illán-Gala I; Dols-Icardo O; Borroni B; Almeida MR; van der Zee J; Van Broeckhoven C; Bruni AC; Anfossi M; Bernardi L; Maletta R; Serpente M; Galimberti D; Scarpini E; Rossi G; Caroppo P; Benussi L; Ghidoni R; Binetti G; Nacmias B; Sorbi S; Piaceri I; Bagnoli S; Antonell A; Sánchez-Valle R; De la Casa-Fages B; Grandas F; Diez-Fairen M; Pastor P; Ferrari R; Álvarez V; Menéndez-González M
    Neurobiol Aging; 2020 Mar; 87():139.e1-139.e7. PubMed ID: 31810584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients.
    Lee T; Li YR; Ingre C; Weber M; Grehl T; Gredal O; de Carvalho M; Meyer T; Tysnes OB; Auburger G; Gispert S; Bonini NM; Andersen PM; Gitler AD
    Hum Mol Genet; 2011 May; 20(9):1697-700. PubMed ID: 21292779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis.
    Chen Y; Huang R; Yang Y; Chen K; Song W; Pan P; Li J; Shang HF
    Neurobiol Aging; 2011 Oct; 32(10):1925.e1-5. PubMed ID: 21741123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Carriers of Intermediate and Pathological Polyglutamine Disease-Associated Alleles Among Large Population-Based Cohorts.
    Gardiner SL; Boogaard MW; Trompet S; de Mutsert R; Rosendaal FR; Gussekloo J; Jukema JW; Roos RAC; Aziz NA
    JAMA Neurol; 2019 Jun; 76(6):650-656. PubMed ID: 30933216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased aggregation of polyleucine compared with that of polyglutamine in dentatorubral-pallidoluysian atrophy protein.
    Suzuki Y; Jin C; Yazawa I
    Neurosci Lett; 2013 Sep; 552():156-61. PubMed ID: 23933208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.